NASDAQ · SCTL
Societal CDMO, Inc.
$1.10+$0.01 (+0.92%)
Societal CDMO, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.06% below the high.
Loading market information…
NASDAQ · OPTN · USD
Stock price, earnings
Quote as of May 21, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
OptiNose, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow OptiNose, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 | Nov 9, 2023 | -$1.20+20.0% vs estimate | $19.82M+3.08% vs estimate |
|---|
| Q2 2023 | Aug 10, 2023 | $0.30+118.18% vs estimate | $19.45M+12.06% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.10+$0.01 (+0.92%)
Societal CDMO, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.06% below the high.
$1.01+$1.01 (+100.0%)
Procaps Group S.A.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
$1.88$0.00 (0.0%)
Jounce Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.99% below the high.
$2.94+$0.07 (+2.44%)
Five Star Senior Living Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.34% below the high.
$0.10-$0.00 (-0.21%)
Zomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.15% below the high.
$0.35+$0.00 (+0.64%)
Asensus Surgical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.87% below the high.
$2.05-$0.05 (-2.38%)
Aadi Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.22% below the high.
$3.39+$0.02 (+0.59%)
Miromatrix Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.07% below the high.
